As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Ardelyx

  • Tuesday's Range: $6.90-$7.79
  • 52-Week Range: $6.84-$22.48
  • Tuesday's Volume: 298,000
  • Three-Month Average Volume: 296,521

Ardelyx  (ARDX)  discovers, develops and commercializes minimally-systemic therapeutics for the gastrointestinal tract to treat GI and cardio-renal diseases. This stock closed up 7.4% to $7.50 in Tuesday's trading session.

From a technical perspective, Ardelyx ripped sharply higher on Tuesday right above some near-term support at $6.88 a share with decent upside volume flows. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $6.84 to $6.88 a share. Following that potential bottom, shares of Ardelyx have now started to spike higher and it's quickly moving within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $8 to its 20-day moving average of $8.24 a share and then above more resistance at $8.26 a share with high volume.

Traders should now look for long-biased trades in Ardelyx as long as it's trending above those recent double bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 296,521 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8.88 to $9.30, or even its 50-day moving average of $9.49 a share.

Flexion Therapeutics

  • Tuesday's Range: $8.15-$9.10
  • 52-Week Range: $7.56-$29.09
  • Tuesday's Volume: 153,000
  • Three-Month Average Volume: 314,898

Flexion Therapeutics  (FLXN) , a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. This stock traded up 5.3% to $9.01 in Tuesday's trading session.

From a technical perspective, Flexion Therapeutics spiked sharply higher on Tuesday right above some near-term support at around $8 a share with lighter-than-average volume. This stock has been downtrending badly over the last four months, with shares collapsing off its high of $21.71 a share to its new 52-week low of $7.56 a share. During that downtrend, shares of Flexion Therapeutics have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock has now started to rebound off that $7.56 low and it's beginning to trend within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out its 20-day moving average of $9.23 a share and then once it clears more resistance at $9.39 a share with high volume.

Traders should now look for long-biased trades in Flexion Therapeutics as long as it's trending above Tuesday's intraday low of $8.15 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 314,898 shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $9.82 to $10.50, or even $11 to its 50-day moving average of $11.48 a share.

Celldex Therapeutics

  • Tuesday's Range: $3.30-$3.73
  • 52-Week Range: $2.96-$30.28
  • Tuesday's Volume: 2.46 million
  • Three-Month Average Volume: 3.96 million

Celldex Therapeutics  (CLDX) , a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the U.S. This stock traded up 6.9% to $3.71 in Tuesday's trading session.

From a technical perspective, Celldex Therapeutics ripped sharply higher on Tuesday right off some near-term support at $3.36 a share with decent upside volume flows. This strong trend to the upside is now quickly pushing shares of Celldex Therapeutics within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some key near-term overhead resistance levels at $4.08 to its gap-down-day high from earlier this month at $4.33 a share with high volume.

Traders should now look for long-biased trades in Celldex Therapeutics as long as it's trending above Tuesday's intraday low of $3.30 a share or above more near-term support at $3 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.96 million shares. If that breakout fires off soon, then this stock will set up to re-fill some of its previous gap-down-day zone that started near $8 a share.

Bellicum Pharmaceuticals

  • Tuesday's Range: $7.57-$8.65
  • 52-Week Range: $7.24-$29.33
  • Tuesday's Volume: 278,000
  • Three-Month Average Volume: 424,403

Bellicum Pharmaceuticals  (BLCM) , a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the U.S.and internationally. This stock traded up 9.2% to $8.64 in Tuesday's trading session.

From a technical perspective, Bellicum Pharmaceuticals exploded sharply higher on Tuesday right off some near-term support at $7.51 a share with lighter-than-average volume. This stock has been downtrending badly over the last five months, with shares collapsing off its high of $23.84 to its new 52-week low of $7.24 a share. During that move, shares of Bellicum Pharmaceuticals have been making mostly lower highs and lower lows, which is bearish technical price action. That said, this stock has now started to rebound sharply off that $7.24 low and it's beginning to trend within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out Tuesday's intraday high of $8.65 a share and then once it clears more key resistance levels at its 20-day moving average of $9.12 a share to $9.15 a share with high volume.

Traders should now look for long-biased trades in Bellicum Pharmaceuticals as long as it's trending above some key near-term support levels at $7.51 to its new 52-week low of $7.24 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 424,403 shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $10 to its 50-day moving average of $10.07, or even $10.30 to around $11 a share.

TG Therapeutics

  • Tuesday's Range: $8.00-$8.75
  • 52-Week Range: $7.32-$19.05
  • Tuesday's Volume: 304,000
  • Three-Month Average Volume: 443,725

TG Therapeutics  (TGTX) , a biopharmaceutical company, focuses on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the U.S. This stock traded up 4.9% to $8.66 in Tuesday's trading session.

From a technical perspective, TG Therapeutics jumped notably higher on Tuesday right above some near-term support at $7.91 a share with lighter-than-average volume. This spike managed to push this stock back above its 50-day moving average of $8.61 a share and right into its 20-day moving average of $8.76 a share. Shares of TG Therapeutics are now quickly trending within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at its 20-day moving average of $8.76 a share and then above more key resistance levels at $9 to $9.17 a share with high volume.

Traders should now look for long-biased trades in TG Therapeutics as long as it's trending above some near-term support levels at $7.91 or $7.86 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 443,725 shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $10 to $10.50, or even $11 a share.

Ocular Therapeutix

  • Tuesday's Range: $8.51-$9.40
  • 52-Week Range: $5.07-$42.78
  • Tuesday's Volume: 176,000
  • Three-Month Average Volume: 322,574

Ocular Therapeutix  (OCUL) , a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the U.S. This stock traded up 8.1% to $9.39 in Tuesday's trading session.

From a technical perspective, Ocular Therapeutix ripped sharply higher on Tuesday right off some near-term support at $8.48 a share and back above its 20-day moving average of $8.76 a share with lighter-than-average volume. This sharp move to the upside is now quickly pushing shares of Ocular Therapeutix within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to clear some near-term overhead resistance levels at $9.50 to $9.70 a share with high volume.

Traders should now look for long-biased trades in Ocular Therapeutix as long as it's trending above some key near-term support levels at $8.48 or $8 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 322,574 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $10.19 to $10.40, or even $11.15 to around $12 a share.

Sangamo Biosciences

  • Tuesday's Range: $5.12-$5.75
  • 52-Week Range: $4.63-$16.18
  • Tuesday's Volume: 903,000
  • Three-Month Average Volume: 1.08 million

Sangamo Biosciences  (SGMO) , a clinical stage biopharmaceutical company, focused on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation. This stock traded up 5.4% to $5.65 in Tuesday's trading session.

From a technical perspective, Sangamo Biosciences spiked sharply higher on Tuesday right above some near-term support at $4.92 a share with decent upside volume flows. This sharp jump to the upside is now quickly pushing shares of Sangamo Biosciences within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to clear some near-term overhead resistance levels at its 20-day moving average of $5.74 a share to its 50-day moving average of $5.75 a share with high volume.

Traders should now look for long-biased trades in Sangamo Biosciences as long as it's trending above Tuesday's intraday low of $5.12 a share or above some more near-term support at $4.92 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.08 million shares. If that breakout kicks off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $6.02 to $6.23, or even $6.68 to $7 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.